Related Experiment Video

Updated: Aug 9, 2026

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer

Astrid Lièvre1, Jean-Baptiste Bachet, Delphine Le Corre

  • 1Université Paris-Descartes, Institut National de la Sante et de la Recherche Medicale UMR-775, Paris, France.

Cancer Research
|April 19, 2006
PubMed

Insights

KRAS mutations predict resistance to cetuximab in metastatic colorectal cancer, worsening patient prognosis. However, increased EGFR copy number may indicate a positive response to this targeted therapy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Cetuximab, an anti-epidermal growth factor receptor (anti-EGFR) therapy, shows efficacy in metastatic colorectal cancer (mCRC).
  • The molecular basis for clinical response to cetuximab is not fully understood.
  • Genetic alterations in EGFR signaling pathways may influence treatment outcomes.

Purpose of the Study:

  • To investigate the association between genetic alterations (KRAS, BRAF, PIK3CA mutations, and EGFR copy number) and response to cetuximab in mCRC patients.
  • To determine if these genetic markers can predict treatment efficacy and patient survival.

Main Methods:

  • Tumor samples from 30 mCRC patients treated with cetuximab were analyzed.
  • KRAS, BRAF, and PIK3CA mutations were detected using direct sequencing.
  • EGFR copy number was assessed via chromogenic in situ hybridization.

Main Results:

  • Eleven out of 30 patients (37%) responded to cetuximab.
  • KRAS mutations (43% of tumors) were significantly associated with non-response (P = 0.0003) and poorer overall survival (P = 0.016).
  • Increased EGFR copy number (10% of tumors) was linked to objective tumor response (P = 0.04).

Conclusions:

  • KRAS mutations serve as a predictive marker for cetuximab resistance in mCRC, correlating with unfavorable prognosis.
  • EGFR amplification, though less common than previously thought, is associated with a positive response to cetuximab treatment.

Related Concept Videos

The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a superfamily...
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...